Skip to main content
Equibles
IMVT logo

IMVT · Immunovant, Inc.

Track IMVT — free

Use IMVT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about IMVT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$41.82 +0.00 (+0.00%) At close · Aug 14
Market Cap
$8.64B
Shares
206.55M

Immunovant, Inc. Earnings Call Transcripts

Every quarterly earnings call for Immunovant, Inc. (IMVT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Annual General Meeting
Investor event
2026-09-02
2026 Annual Meeting of Stockholders
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY27 · Q1
2026-08-06
Roivant 1Q 2026 Earnings Call
Diluted EPS
$-0.75
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q4
2026-05-20
Immunovant, Inc. Q4 FY2026 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY26 · Q3
2026-02-06
Immunovant, Inc. Q3 FY2026 Earnings Call
Confident tone Thyroid Eye Disease (TED) BREPO Phase 2 in Cutaneous Sarcoidosis Graves' Disease / Competitive Landscape
Diluted EPS
$-0.61
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2025-11-10
Immunovant, Inc. Q2 FY2026 Earnings Call
Confident tone Competitive landscape in TED and myositis Batoclimab and IMVT-1402 in Graves' disease Brepocitinib VALOR Phase 3 data in dermatomyositis
Diluted EPS
$-0.73
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2024-11-07
Immunovant, Inc. Q2 FY2025 Earnings Call
Confident tone Competitive landscape in Graves' and TED Batoclimab and IMVT-1402 in Graves' disease Catalyst roadmap and upcoming readouts
Diluted EPS
$-0.74
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2022-08-05
Immunovant, Inc. Q1 FY2023 Earnings Call
Diluted EPS
$-0.35
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-06-08
Immunovant, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q1
2021-08-09
Immunovant, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-0.31
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-06-01
Immunovant, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–10 of 10 earnings calls
Key facts CIK 1764013 CUSIP 45258J102 13F (30d) 223 filings 218 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)